自身免疫性疾病患者的2019冠状病毒病疫苗接种

Q4 Medicine 药物不良反应杂志 Pub Date : 2021-01-01 DOI:10.3760/cma.j.cn114015-20210702-00740

Y. Guan, F. Mu, W. Zhang, Y. Qiao, C. Wang, S. Chen, G. Guo, J. Wang

{"title":"自身免疫性疾病患者的2019冠状病毒病疫苗接种","authors":"Y. Guan, F. Mu, W. Zhang, Y. Qiao, C. Wang, S. Chen, G. Guo, J. Wang","doi":"10.3760/cma.j.cn114015-20210702-00740","DOIUrl":null,"url":null,"abstract":"Benifits outweigh the risks for patients with autoimmune disease (AID) in remission period to be vaccinated with coronavirus disease 2019 (COVID-19) vaccines. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are safe for AID patients, whereas the safety of recombinant adenovirus vector-based vaccines is still uncertain. Some drugs for the treatment of AID may reduce the immune response of the body to the COVID-19 vaccines and affect the immune efficacy of the vaccine, which may be related to the timing of vaccination. Based on several published relevant guidelines and recommendations for the COVID-19 vaccines in AID patients, this article elaborates on vaccination problems to be paid attention to in patients with AID treated with different drugs. Copyright © 2021 by the Chinese Medical Association.","PeriodicalId":7863,"journal":{"name":"药物不良反应杂志","volume":"33 1","pages":"342-347"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Coronavirus disease 2019 vaccination in patients with autoimmune diseases\",\"authors\":\"Y. Guan, F. Mu, W. Zhang, Y. Qiao, C. Wang, S. Chen, G. Guo, J. Wang\",\"doi\":\"10.3760/cma.j.cn114015-20210702-00740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Benifits outweigh the risks for patients with autoimmune disease (AID) in remission period to be vaccinated with coronavirus disease 2019 (COVID-19) vaccines. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are safe for AID patients, whereas the safety of recombinant adenovirus vector-based vaccines is still uncertain. Some drugs for the treatment of AID may reduce the immune response of the body to the COVID-19 vaccines and affect the immune efficacy of the vaccine, which may be related to the timing of vaccination. Based on several published relevant guidelines and recommendations for the COVID-19 vaccines in AID patients, this article elaborates on vaccination problems to be paid attention to in patients with AID treated with different drugs. Copyright © 2021 by the Chinese Medical Association.\",\"PeriodicalId\":7863,\"journal\":{\"name\":\"药物不良反应杂志\",\"volume\":\"33 1\",\"pages\":\"342-347\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药物不良反应杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn114015-20210702-00740\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物不良反应杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn114015-20210702-00740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

处于缓解期的自身免疫性疾病(AID)患者接种2019冠状病毒病(COVID-19)疫苗的益处大于风险。mRNA疫苗、灭活疫苗和重组蛋白亚单位疫苗对艾滋病患者是安全的，而重组腺病毒载体疫苗的安全性仍不确定。一些用于治疗艾滋病的药物可能会降低机体对COVID-19疫苗的免疫反应，影响疫苗的免疫功效，这可能与接种时间有关。本文根据已发表的多份艾滋病患者COVID-19疫苗的相关指南和建议，阐述了不同药物治疗艾滋病患者应注意的疫苗接种问题。中华医学会版权所有©2021。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Coronavirus disease 2019 vaccination in patients with autoimmune diseases

Benifits outweigh the risks for patients with autoimmune disease (AID) in remission period to be vaccinated with coronavirus disease 2019 (COVID-19) vaccines. The mRNA vaccines, inactivated vaccines, and recombinant protein subunit vaccines are safe for AID patients, whereas the safety of recombinant adenovirus vector-based vaccines is still uncertain. Some drugs for the treatment of AID may reduce the immune response of the body to the COVID-19 vaccines and affect the immune efficacy of the vaccine, which may be related to the timing of vaccination. Based on several published relevant guidelines and recommendations for the COVID-19 vaccines in AID patients, this article elaborates on vaccination problems to be paid attention to in patients with AID treated with different drugs. Copyright © 2021 by the Chinese Medical Association.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊